AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Tuesday 10 November 2026
News from the 24 hours to Tuesday morning, 10 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly about a reported $10 billion proposal for Rhythm Pharmaceuticals and a new C4XD licensing deal, both pointing to pipeline expansion. Deutsche Bank's higher price target and positive analyst ratings added to the favourable tone.
What drove it
- Rhythm acquisition proposal
- C4XD licensing deal
- analyst target upgrades
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 4 Nov | +5.0 | 19 |
| Thu 5 Nov | +6.3 | 24 |
| Fri 6 Nov | +4.0 | 37 |
| Sat 7 Nov | +4.5 | 9 |
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
8 stories · 12 headlines · strongest first
Pharma and healthcare on 10 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca analyst ratings and share price +4.22 headlines today · Pieces cite analyst ratings forecasts and the share price on 9 November. | ||
| +5.8 | Analyst ratings with price forecasts well above current levels. | |
| +2.5 | Modest daily share price gain, purely factual update. | |
| AstraZeneca reportedly bids $10bn for Rhythm Pharmaceuticals +3.82 headlines today · 39 in all, since 5 November · Outlets report AstraZeneca proposed a $10 billion acquisition of Rhythm Pharmaceuticals. | ||
| +5.0 | Large proposed acquisition signals growth ambitions in rare disease area. | |
| +4.2 | Commentary on reported interest in big takeover of a biotech. | |
| AstraZeneca C4XD licensing deal +5.02 headlines today · AstraZeneca is tied to a $402 million licensing deal with C4XD. | ||
| +5.0 | New licensing agreement adds to its development pipeline. | |
| +5.0 | Licensing deal valued at hundreds of millions boosts pipeline. | |
| AstraZeneca cancer testing awareness campaign +3.12 headlines today · 3 in all, since 9 November · Coverage describes AstraZeneca's biomarker testing and body-check cancer awareness campaign. | ||
| +3.3 | Its cancer awareness campaign won creative recognition. | |
| +2.5 | Awareness campaign supporting its oncology testing, minor positive. | |
| AstraZeneca price target raised to £120 by Deutsche Bank +8.31 headline today · Deutsche Bank raised its AstraZeneca price target to £120. | ||
| +8.3 | Broker raises price target, showing analyst confidence. | |
| EU JCA report published for AstraZeneca's Etcamah +3.31 headline today · The European Commission published its fifth EU joint clinical assessment report, for AstraZeneca's Etcamah. | ||
| +3.3 | EU regulatory assessment report published for its drug, a procedural step forward. | |
| AstraZeneca hypertension care article +1.71 headline today · AstraZeneca published a piece on closing hypertension care gaps. | ||
| +1.7 | Company-published piece on cardiovascular care, mildly positive. | |
| AstraZeneca speculated as possible Sobi bidder +1.71 headline today · A piece considers whether AstraZeneca might pursue Sobi. | ||
| +1.7 | Speculation about possible interest in a Swedish biotech target. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.